OpenAI Launches ChatGPT Health: 5 Things to Know
Katie Adams / medcitynews - OpenAI announced a new dedicated platform for health conversations. The company said the new offering is not intended for medical diagnosis or treatment — but rather to provide support for personal health navigation.The post OpenAI Launches ChatGPT Health…
AI Summary: OpenAI has rolled out ChatGPT Health, a dedicated platform enabling health‐focused conversations by integrating data from health apps and medical records. Although not intended for diagnosis, the move sparks wry remarks as the tech giant ventures boldly into sensitive, regulated health terrain.
RFK Jr.'s CDC whacks 6 vaccines from childhood recommendation list after opaque monthlong review
fiercehealthcare - The Centers for Disease Control and Prevention (CDC) has upended the immunization schedule for children in the United States, eliminating six of the 17 vaccines that were previously recommended to protect them from disease.
AI Summary: In an unexpected twist to the longstanding immunization program, the CDC has eliminated six previously universal childhood vaccines following a monthlong review—sparking debates and eyebrow raises among healthcare officials. The policy change now tailors recommendations to higher-risk groups while shifting away from a one‐size‐fits‐all approach.
UK starts ban on junk food ads on daytime TV and online
medicalxpress - New regulations come into force Monday in Britain banning daytime TV and online adverts for so-called junk foods, in what the government calls a "world-leading action" to tackle childhood obesity.
AI Summary: British regulators have implemented new rules banning junk food advertisements on daytime TV and online platforms. The measures—targeting products like soft drinks, chocolate, pizza, and ice cream—are part of a government drive to curb unhealthy food marketing and protect public health, especially among younger audiences.
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome
Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company
AI Summary: Corcept Therapeutics has hit a regulatory roadblock as the FDA rejected its cortisol‐targeting relacorilant, intended for hormonal disorders. The decision forces the company to reassess its strategy, highlighting the challenges inherent in advancing novel hormonal therapies amid strict regulatory scrutiny.
Low-dose peanut therapy shown to protect children with peanut allergies
medicalxpress - Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and Montreal Children's Hospital.
AI Summary: Emerging study results indicate that administering lower doses of peanut oral immunotherapy can build effective resistance in children with peanut allergies while minimizing adverse side effects. This finding could lead to safer, more accessible treatment protocols that transform current clinical practices and improve overall patient outcomes for pediatric allergy management.
Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer
oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
AI Summary: Researchers reveal that an increased bacterial burden within head and neck tumors may undermine the efficacy of immune checkpoint blockade treatments. Detailed investigations indicate that intratumoral bacteria could be a pivotal factor in treatment resistance, opening new avenues for overcoming these challenges in managing advanced head and neck cancers.
Maimonides Health to merge with NYC Health + Hospitals supported by $2.2B state grant
fiercehealthcare - Brooklyn, New York-based Maimonides Health is merging with New York City's public health system NYC Health + Hospitals, the organizations announced Monday.
AI Summary: Brooklyn-based Maimonides Health is merging with New York City’s public health system, bolstered by a $2.2 billion state grant. The integration is expected to streamline services and strengthen healthcare delivery in the region, ultimately broadening patient access and improving community care.
Judge blocks 340B rebate pilot program
Ella Jeffries / beckershospitalreview - A federal judge granted a temporary restraining order blocking the Department of Health and Human Services from launching its 340B Rebate Model Pilot Program, which was scheduled to begin Jan. 1, 2026. U.S. District Judge Lance Walker of the District of M…
AI Summary: A federal judge has temporarily halted the rollout of a 340B rebate pilot program designed to reshape drug pricing ahead of its January start. The ruling challenges the current administration’s approach to reforming pricing models, casting uncertainty on the initiative’s future.
Advocates Applaud DEA’s Fourth Extension of Remote Prescribing Flexibilities
Marissa Plescia / medcitynews - The DEA extended telemedicine prescribing flexibilities for controlled substances through the end of 2026, drawing praise from telehealth advocates who are urging a permanent solution.The post Advocates Applaud DEA’s Fourth Extension of Remote Prescribing…
AI Summary: The Drug Enforcement Administration has extended telemedicine prescribing flexibilities for controlled substances through 2026, maintaining the COVID-era approach. Telehealth advocates are cheering the move as it cements remote care as a long-term fixture, even as regulators and critics continue debating its broader safety implications.
Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
medicalxpress - Many consumers feel pride in avoiding the glazed pastries in the supermarket and instead opting for "all natural" granola that comes packed with extra protein. Same goes for low-fat yogurts "made with real fruit," "organic" plant-based milks and bottled "…
AI Summary: Investigative posts reveal that foods flaunting “all‐natural” or “healthy” buzzwords can secretly pack in a surprising amount of added sugars, leaving consumers to wonder if their guilt‐free choices are anything but sweet. A reminder that not every label is as wholesome as it sounds.
Johns Hopkins Hospital names associate chief medical officer
Ella Jeffries / beckershospitalreview - Baltimore-based Johns Hopkins Hospital has named Kavita Sharma, MD, as associate chief medical officer, effective Jan. 6. Dr. Sharma announced her new role in a Dec. 22 post on X, writing that she is “grateful for patients who allow us the privilege of ca…
AI Summary: Johns Hopkins Hospital in Baltimore has announced that Dr. Kavita Sharma will serve as its new associate chief medical officer, effective January 6. Both reports confirm the leadership change as the institution aims to further strengthen its clinical operations and strategic direction.
'Don't use them': Tanning beds triple skin cancer risk, study finds
medicalxpress - When Heidi Tarr was a teenager, she used a tanning bed several times a week with her friends because they all wanted to glow like a celebrity.
AI Summary: Recent studies warn that using tanning beds dramatically increases skin cancer risk—one report shows a threefold surge in risk while another links tanning to significant skin mutations and melanoma. Experts urge consumers to steer clear and embrace safer alternatives.
HHS targets information-blocking, certification cuts in new rule
Naomi Diaz / beckershospitalreview - The U.S. Department of Health and Human Services on Dec. 22 proposed a rule that would significantly reduce federal health IT certification requirements, revise information-blocking policies and establish a framework to support AI-enabled interoperability…
AI Summary: The U.S. Department of Health and Human Services has proposed a sweeping new rule aimed at slashing nearly 34 of the existing 60 health IT certification requirements. The move is designed to curb information blocking and reduce administrative burdens, signaling a major policy shift for healthcare technology.
19 states, DC sue HHS over gender-affirming care restrictions
Kristin Kuchno / beckershospitalreview - A coalition of 19 states and Washington, D.C., have filed a lawsuit challenging a declaration from HHS Secretary Robert F. Kennedy Jr. that threatens to cut off federal funding to hospitals that provide certain gender-affirming care to minors. Here are se…
AI Summary: A coalition of 19 states and Washington D.C. has filed lawsuits against HHS, challenging recent regulatory moves that could restrict access to gender‑affirming care for youth. The legal battle highlights rising state-level resistance aimed at protecting transgender healthcare rights amidst intense political debate.
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
AI Summary: Two separate reports confirm that Sanofi has completed a $2.2 billion deal to acquire Dynavax Technologies. This strategic move strengthens Sanofi’s vaccine lineup by adding a commercially proven hepatitis B vaccine and a clinical‐stage shingles candidate, positioning the company for enhanced market competitiveness amid global pressures.
Mark Cuban says these 8 habits are why most people never make it in life (and what to do instead)
James Brennan / siliconcanals - Mark Cuban reveals the shocking daily habits that separate billionaires from everyone else—and why your morning routine might be sabotaging your success before you even leave the house.
AI Summary: A landmark announcement spotlighted the 100 most influential figures in oncology—spanning clinicians, researchers, and advocates—whose work is driving transformative change in cancer care worldwide. The recognition sets new benchmarks and inspires a future of innovation and collaboration in oncologic practice.
- Breakthrough Research & Clinical Trials (17)
- OncoDaily Honorees: Leading Oncology Voices (2)
- Oncology Community & Patient Advocacy Spotlights (18)
- Other: Business and Tech News (2)
- All Other Stories
Breakthrough Research & Clinical Trials
OncoDaily Honorees: Leading Oncology Voices
Oncology Community & Patient Advocacy Spotlights
Other: Business and Tech News
All Other Stories
Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss
Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…
AI Summary: The FDA has given its nod to Novo Nordisk’s oral GLP‑1 receptor agonist for chronic weight management – a historic first for an anti‑obesity pill. The approval offers patients a non‑injectable alternative, potentially transforming obesity care in a market hungry for innovation.
Medline raises IPO to $6.3B
Ella Jeffries / beckershospitalreview - Medline priced its upsized initial public offering at $29 per share for 216,034,482 shares of Class A common stock, according to a Dec. 16 news release from the company. Shares are expected to begin trading Dec. 17 on the Nasdaq Global Select Market under…
AI Summary: Medline’s initial public offering has burst onto the market with a valuation around $6.3B, making it one of the year’s largest healthcare IPOs. The debut has generated significant investor buzz and underscores a strong current of market confidence in the company’s prospects.
FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]
AI Summary: The FDA has granted full approval to rucaparib (Rubraca®) for treating adults with BRCA‐mutated metastatic castration‐resistant prostate cancer, converting its prior accelerated approval into standard approval. This landmark decision offers a new treatment option for patients with this genetic profile.
FDA Removes Key Limitation on the Use of Real-World Evidence in Regulatory Reviews
oncodaily - On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant update to its regulatory approach regarding the use of real-world evidence (RWE) in drug and medical […]
AI Summary: The FDA has dramatically loosened its long‐standing limitations on the use of real‐world evidence in regulatory reviews, signaling an era where big data may facilitate quicker approvals for innovative drugs. Officials are also urging early-phase trials reform to better capture real‐world outcomes.